Today: 20 May 2026
Browse Category

LSE:HLN 5 January 2026 - 22 April 2026

FTSE 100 Today: Why London Stocks Are Stuck Near 10,500 as Inflation Bites

FTSE 100 Today: Why London Stocks Are Stuck Near 10,500 as Inflation Bites

UK inflation rose to 3.3% in March, driven by higher motor fuel prices, the Office for National Statistics said Wednesday. The FTSE 100 hovered near 10,500, down 0.04%, as losses in Reckitt and JD Sports offset gains in miners and BP. Reckitt fell 5% after missing sales forecasts and warning on margins. Investors weighed whether the inflation jump could prompt a tougher Bank of England stance.
22 April 2026
·········
Haleon share price edges up in London trade ahead of Feb 25 results

Haleon share price edges up in London trade ahead of Feb 25 results

Haleon shares rose 0.1% to 409.9 pence in early London trading Monday, near a 52-week high. The company will report full-year 2025 results Wednesday, with investors watching for updates on organic sales growth, cash returns, and 2026 guidance. Haleon previously flagged about 3.5% organic revenue growth for 2025 and a currency headwind. A £500 million share buyback for 2025 is set to complete.
23 February 2026
··
Haleon share price rises as UK inflation cools — what to watch before Feb 25 earnings

Haleon share price rises as UK inflation cools — what to watch before Feb 25 earnings

Haleon shares rose 0.9% to 412.6 pence in early London trading Wednesday, tracking gains in the UK market after softer inflation data. The stock traded between 410.60 and 414.80 pence, nearing its 52-week high. UK inflation slowed to 3.0% in January, fueling rate-cut bets. Haleon’s updated analyst consensus shows FY2025 revenue at £11.08 billion and organic growth of 3.4%.
18 February 2026
····
Haleon shares close higher in London as investors turn to Feb. 25 results

Haleon shares close higher in London as investors turn to Feb. 25 results

Haleon shares rose 2% to 379 pence Friday, outperforming the London market as the FTSE 100 logged a seventh straight monthly gain. About 14.1 million Haleon shares traded between 371.1 and 379.3 pence. The company will report full-year results on Feb. 25 and plans a major operating overhaul, including a new chief growth officer. GSK also gained 1.3% in London trading.
31 January 2026
·
Haleon share price slips in London as investors wait for the next big update

Haleon share price slips in London as investors wait for the next big update

Haleon shares dipped 0.1% to 361.8 pence in early London trading Friday after a 1.1% drop Thursday, with about 1 million shares changing hands. The move follows a recent reorganisation announcement as investors await full-year results on Feb. 25. European stocks also edged lower, pressured by a 1% decline in mining shares. Haleon has not issued new regulatory news since early January.
16 January 2026
·
Haleon stock today: shares slip as JD Health China deal lands and Deutsche Bank turns bearish

Haleon stock today: shares slip as JD Health China deal lands and Deutsche Bank turns bearish

Haleon shares fell 0.5% to 364.5 pence in early London trading after Deutsche Bank downgraded the stock to “sell” and cut its price target to 340 pence. JD Health and Haleon announced a new deal to expand their partnership in China beyond chronic disease management. Investors await Haleon’s full-year results on Feb. 25. Financial terms of the China deal were not disclosed.
15 January 2026
·
Haleon PLC stock slides on operating model shake-up as investors look to Feb. 25 results

Haleon PLC stock slides on operating model shake-up as investors look to Feb. 25 results

Haleon shares fell 1.18% to 367.50p Friday after announcing a major operating overhaul, splitting its EMEA and Latin America regions and creating a standalone India Subcontinent unit. New senior roles include Filippo Lanzi as Chief Growth Officer and Björn Timelin as Chief Transformation Officer. The changes are set for mid-2026. Haleon’s market value stands at about £32.7 billion.
10 January 2026
··
Haleon PLC stock edges lower after executive share-deal filing, with earnings in focus

Haleon PLC stock edges lower after executive share-deal filing, with earnings in focus

Haleon shares fell 0.4% to 375.2 pence in early London trading after two senior executives disclosed small share purchases under the company’s reward plan. The transactions, involving 34 partnership shares each by the general counsel and chief marketing officer, were filed Tuesday. Investors are now looking ahead to Haleon’s full-year results and 2026 guidance on Feb. 25.
7 January 2026
··
1 2

Stock Market Today

  • Stock Market Continues Modest Pullback as Leading Growth Stocks Hold
    May 19, 2026, 7:45 PM EDT. The stock market extended its losing streak to three sessions on Tuesday, marking a modest and orderly pullback. Despite the slump, leading growth stocks demonstrated resilience, showing signs of underlying strength amid broader market pressure. Investors are watching carefully as the overall market digests recent gains, while specific oil and gas companies attract attention for potential opportunities. This cautious environment suggests investors are balancing profit-taking with selective buying in sectors showing robust performance.

Latest articles

GCL Global Stock’s Wild After-Hours Jump: The $10 Million ADATA Deal Behind the Move

GCL Global Stock’s Wild After-Hours Jump: The $10 Million ADATA Deal Behind the Move

20 May 2026
GCL Global Holdings shares jumped to $1.00 after hours Tuesday, up 132%, following news that ADATA Technology invested another $10 million in its 4Divinity unit. The stock had closed regular trading at $0.43, below Nasdaq’s $1 minimum. Recent filings still warn of listing and execution risks. GCL reported first-half revenue up 94% to $98.7 million but posted a net loss of $5.6 million.
James Hardie Drops After Warning on Housing, Even With Q4 Beat

James Hardie Drops After Warning on Housing, Even With Q4 Beat

20 May 2026
James Hardie’s U.S.-listed shares dropped 6.1% Tuesday and slid another 2.6% after hours after reporting a 35% fall in quarterly net income to $28.5 million, despite a 45% jump in net sales to $1.40 billion. The company cited weak housing demand and warned the market remains uncertain. ASX shares had not traded post-earnings; they last closed at A$26.78, up 2.9%.
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

20 May 2026
SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
Go toTop